NeuroSense Therapeutics Ltd. (NRSN) stock
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
$1.51−0.05 (-3.51%)
Close on Nov 17, 2026Market cap $2.77MP/E –Yield –
NeuroSense Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
NeuroSense Therapeutics's enterprise value was $3.04M on Nov 11, 2026, against $28.61M a year earlier. Over the last 5 years it ranged from -$8.24M to $40.52M, with a median of $15.44M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.04M | -83.4% |
| 2025 | Dec 31, 2025 | $18.25M | -10.8% |
| 2024 | Dec 31, 2024 | $20.46M | – |
| 2023 | Dec 29, 2023 | -$6.99M | -313.9% |
| 2022 | Dec 30, 2022 | $3.27M | – |
See a number that looks wrong?